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Abstract
Objective: To explore genes of the killer-cell immunoglobulin-like receptor (KIR) and of the HLA ligand and their
relationship with the outcome of metastatic colorectal cancer (mCRC) patients treated with first-line 5-fluorouracil,
leucovorin, and irinotecan (FOLFIRI).
Methods: A total of 224 mCRC patients were screened for KIR/HLA typing. The determination of the KIR/HLA combinations
was based upon the gene content and variants. Genetic associations with complete response (CR), time to progression (TTP)
and overall survival (OS) were evaluated by calculating odds and hazard ratios. Multivariate modeling with prognostic
covariates was also performed.
Results: For CR, the presence of KIR2DL5A, 2DS5, 2DS1, 3DS1, and KIR3DS1/HLA-Bw4-I80 was associated with increased CR
rates, with median ORs ranging from 2.1 to 4.3, while the absence of KIR2DS4 and 3DL1 was associated with increased CR
rates (OR 3.1). After univariate analysis, patients that underwent resective surgery of tumor, absence of KIR2DS5, and
presence of KIR3DL1/HLA-Bw4-I80 showed a significant better OS (HR 1.5 to 2.8). Multivariate analysis identified as
parameters independently related to OS the type of treatment (surgery; HR 2.0) and KIR3DL1/HLA-Bw4-I80 genotype (HR for
T-I80 2.7 and for no functional KIR/HLA interaction 1.8). For TTP, no association with KIR/HLA genes was observed.
Conclusion: This study, for the first time, evidences that the genotyping for KIR-HLA pairs are found predictive markers
associated with complete response and improves overall survival prediction of FOLFIRI treatment response in metastatic
colorectal cancer. These results suggest a role of the KIR/HLA system in patient outcome, and guide new research on the
immunogenetics of mCRC through mechanistic studies and clinical validation.
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Introduction
The innate immune system is the first line of defense in response
to tumor cell. Natural Killer (NK) cells perform an important role
in this response with their ability to kill tumor cells, produce
cytokines, and cross-talk with the adaptive system. Interactions
between killer-cell immunoglobulin-like receptors (KIR)-receptors
and human leucocyte antigen (HLA)-ligand regulate the response
of NK cells, resulting in a multitude of KIR/HLA combinations
and different NK effects. Modification of tumor-cell due to
chemotherapeutic-treatment may also contribute to a difference in
NK-response.
Similar to other combination regimens in metastatic colorectal
cancer (mCRC), treatments based upon FOLFIRI (5-fluorouracil,
leucovorin and irinotecan), used in about 60% of first-line
treatment in Europe [1], remain ineffective in a significant
proportion of patients [2]. Immunotherapy aimed at enhancing
natural antitumor T-cell immunity in patients affected by
advanced malignancies are currently being implemented in the
clinic with promising results, often showing a synergic effect with
chemotherapy [3]. In order to optimize therapeutic protocols and
monitor the effectiveness of such therapies, acknowledgement of
the exact mechanisms that modulate action of the host immunity
resulting in an effect on patient outcome are not entirely clear and
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could involve different T-cell receptors and immune cells. Further
work is needed to fill the remaining gaps in our knowledge.
Pathological staging is the only prognostic classification used in
clinical practice to select patients for chemotherapy. Gene
expression profiling, which however require primary tumor
samples, might contribute to the classification and prognostic
value prediction of colon cancer [4]. Additional factors, preferably
easily available, to identify patients at the highest risk for
recurrence (prognostic factors) as well as to predict those most
likely to benefit from chemotherapy (predictive factors) are usefull
to improve the selection of patients for adjuvant chemotherapy.
Moreover novel Response Evaluation Criteria in Solid Tumor
(WHO criteria), designed immune-related response criteria (irRC)
to evaluate antitumor responses to chemotherapeutic agents, is
increasingly resulting in a better assessment of anti-tumor agents
[5] for more frequent use of immunotherapy and immune-
chemotherapy in cancer patients [6;7].
Different types of infiltrating immune cells have different effects
on tumor progression [8]. NK cells can affect tumor progression
and could represent a surrogate marker of response of the host
immunity against cancer cells, including CRC [9;10]. NK cell
infiltration in situ was found to be minimal within surgically
resected CRC samples, as opposed to the higher numbers of NK
cells in the adjacent normal mucosa [11]. Accumulating evidence
indicates that overexpression of the HLA-E on CRC cells leads to
inhibition of NK cell-mediated anti-tumor response by engaging
CD8 T cells and NK cell subsets [12].
NK cells, traditionally considered as part of the innate immune
system, have also been shown to share many functions with
adaptive immunity [13;14]. Contribution of KIR/HLA interac-
tion to signaling in NK cells are not fully understood [15], but
their importance has been underscored by several recent genetic
studies which have linked KIR/HLA-combinations with the
outcome of various diseases, and with some clinical response to
treatment, including the one in this study. NK cells preferentially
kill target cells that express few or no HLA class-I molecules on
their surface. The activity of NK cells is regulated by a balance of
transducer signals through activating and inhibitory receptors
[16].
Most NK receptors appear to belong to a family known as
KIRs. They are expressed in NK cells and in a small subset of T
lymphocytes. The KIR receptors are either inhibitory (with long
(L) tails, i.e. KIR2DL1) or activating (with short (S) tails, i.e.
KIR2DS1). A distinct KIR typically interacts with a specific
allotype of an HLA class-I molecule [15;17]. Each NK cell can
express several different inhibitory and/or activating receptors
that function independently from each other. Consequently, there
is a relatively high level of pleiotropy and heterogeneity of KIRs in
humans. The independent expression of polymorphic KIR genes
and highly polymorphic HLA ligands determines the final NK cell
function [15;18].
Cytotoxic agents can activate different pathways of cell death,
inducing distinct peptide patterns of HLA cross-presentation of
tumor-released antigens to cytotoxic T-cells, including NK cells
[19]. A higher rate of tumor-associated antigen uptake by HLA-
mediated antigen-presenting cells has been reported after the
administration of 5-FU [20]. The anti-tumor effects of chemo-
therapy could be further enhanced by NK cell functions [21–25].
Because of the emerging role of the immune system in solid
tumor biology [26], the potential role of immune effectors in
mediating the efficacy of therapy [3;25] and the lack of clinical
information on the role of the KIR/HLA system in mCRC, we
aimed to: 1) characterize the genetic profile of the KIR/HLA
system in an homogeneous group of mCRC patients treated with
FOLFIRI, and 2) determine the effect of the patient genetic
makeup of the KIR/HLA system on response rate and survival.
For this purpose, we developed a KIR/HLA pair genotyping to
characterize the spectrum of NK-related immune genes in CRC
response to FOLFIRI treatment in univariate and multivariate
analysis. We discuss here the studies relating to highly polymor-
phic KIR/HLA interactions with an emphasis on how these genes




We used outcome data collected from a previous study, and
eligibility criteria and FOLFIRI treatments have been previously
described in details [27] For this study we selected patients with a
stage IV and recurrent CRC. Patients were treated in first line
with FOLFIRI only, and no biological therapies were allowed.
The patients evaluable for objective response, time to tumor
progression (TTP) and overall survival (OS) were 224.
The median duration of follow-up was 21.73 months (range:
1.07–91.8). Response rates were as follows: complete response
(CR, n = 15), partial response (PR, n = 80), stable disease (SD,
n = 62), and progressive disease (PD, n = 67). Tumor response was
Table 1. Characteristics of the mCRC patients treated with
FOLFIRI.



























$ Radical surgery: Surgical resection of locally recurrent cancer.
doi:10.1371/journal.pone.0084940.t001
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assessed using the WHO criteria as previously reported [28]. OS
was defined as the time from the first drug administration to date
of death or last follow-up. Patients alive at the last follow-up were
censored. TTP was defined as the time from the date of the initial
therapy to the earliest date of tumor progression or last follow-up.
The median OS was 21.7 months (range: 1.07–91.8). The median
TTP was 8.5 months (range: 0.7–41.6). Patient characteristics are
shown in Table 1.
KIR and HLA Genotyping
DNA was extracted from blood using the EZ1 Qiagen Italy kit
as previously described [29]. Patients were genotyped for the
presence of the KIR genes (2DL1-4, 2DL5A and 2DL5B, 3DL1-3,
2DP1, 2DS1-3, 2DS4, 2DS5, 3DP1, and 3DS1) using a multiplex
polymerase chain reaction-sequence specific primer reaction,
optimized in our laboratory [30].
High resolution HLA class-I analysis was performed by PCR
sequence-based typing with primers specific for loci A, B and C
and the use of the Assign SBT software (version 3.27b) [30]. KIR
and HLA gene frequencies were representative of those of a
Caucasian population [31] and were comparable to those found in
our series of non cancer blood donors (data not shown).
Analysis of the KIR-HLA Genes
The KIR gene content shows a high degree of variation, in
terms of number and type of genes present. Two main KIR
haplotype groups have been described, based on gene content, and
are designated as A and B [32;33]. The group A haplotypes have a
simple and constant gene content, represented by genes encoding
inhibitory receptors KIRs 2DL1, 2DL3, 2DL4, 2DS4, 3DL1,
3DL2 and 3DL3. In contrast, the group B haplotypes have more
variable and greater gene content, involving genes encoding
distinctive inhibitory receptors and a variety of activating
receptors.
The associations of KIRs with their cognate HLA ligands were
established on the basis of predicted KIR/HLA combinations,
according to a standard classification [34]. HLA-A, -B and -C
molecules were placed into 3 groups (HLA-C1, -C2, and Bw4)
based on the amino acid sequences determining the KIR-binding
epitope. HLA-C allotypes with asparagine at position 80 (HLA-
C1) are ligands for the KIRs 2DL2, 2DL3, and 2DS2; HLA-C
allotypes with lysine at position 80 (HLA-C2) are ligands for the
KIRs 2DL1 and 2DS1. In the third group, HLA-A and -B
allotypes with the Bw4 epitope are ligands for KIRs 3DL1 and
3DS1 and are distinguished by substitutions at position 77, 80, 81,
82 and 83 in the C terminus of the HLA class I a1 domain; HLA-
Figure 1. Association between the number of activating KIR (aKIR) genes and complete response (CR) rate. The KIR gene analysis
shows a trend (chi squared test for trend, p,0.001) between an increasing number of aKIR genes (KIR2DS3 and KIR2DS5; ligand unknown) or aKIR/
HLA-ligand (KIR2DS1/HLA-C2, KIR2DS2/HLA-C1, KIR2DS4full/HLA-Cw*04, KIR3DS1/HLA-Bw4) and the rate of CR.
doi:10.1371/journal.pone.0084940.g001
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A*03 and *11 are ligands for KIR3DL2 and HLA-C*04 is a ligand
for KIR2DS4 [35].
Statistical Analysis
Odds ratios (OR) and 95% confidence intervals (CI) were used
to investigate the association between KIR/HLA genes and
tumour response (CR, PR, SD and PD). TTP and OS were
computed by using the Kaplan-Meier method, and the log-rank
test was used to test the differences between subgroups. Cox
proportional hazard regression models were used to calculate
hazard ratios (HR) and 95% CIs. Fisher’s exact test and chi-
squared analysis for trend were also used to test the effect of KIRs
and HLAs on CR. The independence of the genetic associations
from tumor and clinical characteristics was tested by multivariate
modeling of covariates, including sex, age, tumor location (rectum;
right colon; left-colon), TNM stage at diagnosis, radical surgery
(surgical resection of locally recurrent cancer). Results were
considered to be statistically significant when p,0.05 (two-sided).
All analyses were carried out by using SAS 9.2 statistical software
(SAS Institute, Inc., Cary, NC).
Ethics Committee Approval
The study was coordinated and sponsored by the Centro di
Riferimento Oncologico, National Cancer Institute, Aviano, Italy,
accordantly to Declaration of Helsinki Principle. The use of blood
sample collection was approved by CRO, institutional Board: RC
linea 4. All patients provided written informed consent for genetic
analysis before entering the study, this consent was considered
sufficient and approved by the Institutional Review Board.
Results
Associations of HLA/KIR with Complete Response Rates
Presence of KIR2DL5A, 2DS5, 2DS1, 3DS1 and KIR3DS1/
HLA-Bw4-I80 was associated with improved CR rates (CR versus
PR+SD+PD) with ORs ranging from 2.1 to 4.3 (p,0.05, Table 2).
Conversely, absence of KIR2DS4 and 3DL1 was associated with
an improved CR (OR 3.1, 95% CI 0.0–0.5, p 0.001, Table 2).
KIR haplotype analysis indicated that the B/B haplotype,
including KIR2DL5A, 2DS1, 2DS5, and 3DS1, but not
KIR2DS4, was more frequent in patients with CR (33.3%) than
in other patients (4.8%) (OR 5.45, 1.5–19.1, p 0.013). A/A and A/
B haplotypes contain only KIR2DS4 as the single activating KIR
gene, in agreement with the concept that activating KIR (aKIR)
genes are usually associated only with the group B haplotype, an
increasing number of aKIR genes (with their cognate HLA carrier)
was associated with improved CR (p,0.001, Fig. 1). None of the
patients and tumor characteristics listed in Table 1 was associated
with CR rates (p.0.05, data not shown).
Analysis of KIR and their HLA ligands genotyping, showed a
higher CR rate when combining KIR3DS1 with HLA-Bw4-I80
than when combined either with HLA-Bw4-T80 or HLA-Bw6
(not recognized by KIR3Ds) or in case of absence of the KIR3DS1
gene, respect to other patients (PR+SD+PD) (Table 2). Among
different KIR genes, the activating KIR3DS1 and the inhibitory
KIR3DL1 segregate as alleles of the same KIR3DL1/S1 locus and
KIR3DL1 and putatively KIR3DS1 are receptors for a same
subset of HLA-B alleles. Within the HLA-Bw4-I80 ligand, the 3
different combinations of KIR3DS1 and KIR3DL1 (i.e. presence/
absence, presence/presence, absence/presence, respectively) were
suggestive of a trend for increased CR rate in the presence of
KIR3DS1 (p 0.016, Fig. 2).
Associations of HLA/KIR with Overall Survival and Time to
Progression
Among patient characteristics, only surgical resection of locally
recurrent cancer improved the OS rates in comparison with
patients who did not have surgical resection (median 25.1 vs 14.4
months, HR 2.1, p,0.001, Figure 3A, Table 3 and Table S1).
Among genotypes (Table S1), the presence of KIR2DS5 gene
(Figure 3B) and KIR3DL1/HLA-Bw4-I80 (Figure 3C) was
associated with improved OS, while KIR3DL1/HLA-Bw4-T80
(HR 2.8, p,0.001) or a non interacting KIR3DL1 receptor (2/2)
(HR 1.8, p 0.007) was associated with worse OS. Median OS was
25.1 months in KIR2DS5 patients, 29.4 months (22.7–43.0) in
KIR3DL1/HLA-Bw4-I80 patients, 14.7 months (11.7–22.3) in
KIR3DL1/HLA-Bw4-T80 patients, and 21.6 months (18.6–26.7)
in patients without KIR3DL1/HLA-Bw4 (either I80 or T80 or
absence of KIR3DL1).
In multivariate analysis including the only clinical characteristic
associated with OS (radical surgery) and KIR/HLA genotypes,
surgery and KIR3DL1/HLA-Bw4-I80 retained an independent
effect on OS (HR 2.0, p,0.001 and HR 2.7–1.8, p,0.001–0.006,
respectively) (Table 3). The effect of compound patients who had
(or not) radical surgery, who had (or not) KIR2DS5 gene that is
partially in linkage disequilibrium with KIR3DL1 (http://www.
allelefrequencies.net/kir6010a.asp. Accessed 2012 ctober 17), and
KIR3DL1/HLA-B pairs on the OS is illustrated in Figure 3D.
Median OS was 43.0 months in patients treated with surgery,
without KIR2DS5 but KIR3DL1/Bw4-I80+ genotype and 13.7
months in patients without surgery treatment and having a
Table 2. Association between KIR/HLA and complete
response (CR) rate.
CR% PR+SD+PD% OR (95% CI) p
KIR2DL5A
– 26.7 59.8 1
+ 73.3 40.2 4.1 (1.3–13.3) 0.02
KIR2DS5
– 40.0 67.0
+ 60.0 33.0 3.0 (1.0–8.9) 0.04
KIR2DS1
– 26.7 59.8 1
+ 73.3 40.2 2.1 (1.3–13.3) 0.02
KIR3DS1
– 26.7 60.8 1
+ 73.3 39.2 4.3 (1.3–13.8) 0.02
KIR2DS4
+ 33.3 6.2 1
– 66.7 93.8 3.1 (0.0–0.5) 0.001
KIR3DL1
+ 66.7 93.8 1
– 33.3 6.2 3.1 (0.0–0.5) 0.001
KIR3DS1/HLA-Bw4
2/2 46.7 74.2 1
+/T80 13.3 9.6 2.2 (0.4–11.4) 0.34
+/I80 40.0 16.3 3.9 (1.2–12.4) 0.02
CR: complete response; PR: partial response; SD: stable disease; PD: progressive
disease. + and 2 refer to presence and absence of a gene (respectively).
doi:10.1371/journal.pone.0084940.t002
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genotype including KIR2DS5 but no KIR3DL1/HLA-Bw4-I80
pair genes.
For the analysis of TTP, neither individual KIR genes nor
combinations of KIR/HLA genes were significantly associated
with TTP (p.0.05, data not shown).
Discussion
The study, for the first time, has investigated the clinical
relevance of KIR/HLA gene combinations in mCRC patients and
FOLFIRI treatment. Depending upon the KIR/HLA combina-
tion, tumor response and OS differed among patients who had
similar clinical and tumor characteristics. Only two studies have
investigated the distribution of KIR and HLA genes in CRC
specimens [36;37], but these studies analyzed only KIR/HLA
frequencies in cancer patients compared to normal control subjects
with the aim to test the impact of KIR/HLA status on individual’s
susceptibility to CRC.
Advances have been made in the last years in metastatic
colorectal cancer treatments, with the introduction of novel
molecularly targeted agents like antibodies against the VEGF or
the EGFR targets; nonetheless rate of long survivors are low. NK
cells provide first-line defense against malignantly transformed
cells [38;39] and recent evidence of the use of antibodies blocking
the immunosuppressive receptor programmed cell death 1 (PD-1)
pathway underscored the central role of reinduction of host
immune system and of potentiating the NK-cell mediated
cytotoxicity in several tumor prognosis [40;41] including CRC
[3]. Moreover, some of the clinically approved therapeutic
antibodies to treat cancer, such as cetuximab and rituximab, are
considered to function partially through triggering NK cell
mediated ADCC activity [42]. Overall, despite the central role
of NK-cells in host immune responses and the fact that the KIR/
HLA gene system is the principal receptor system able to modulate
NK cell function, KIR/HLA genotypes on the clinical outcome in
mCRC has been essentially unexplored.
The analysis of the KIR/HLA genetic make-up of mCRC
patients proposes that presence of KIRs 2DL5A, 2DS5, 2DS1 and
3DS1/HLA-Bw4 ligand pair and absence of the KIR2DS4 and
3DL1 (Table 2, Figs 1–2) might influence the likelihood of
achieving a radiologic response after chemotherapy. Thus, in our
series patients showing a more activator haplotype (eg haplotype
B/B), and especially KIR3DS1/HLA-Bw4-positive NK cells in
Figure 2. KIR3D and HLA-B ligands and their association with the CR rate. The NK effector functions are determined by the cumulative
signal generated via the ligation of activating and inhibitory NK cell receptors with their putative HLA ligand on target cells. Activating (KIR3DS1) and
inhibitory (KIR3DL1) receptors are genes of a same locus and have similar HLA-B ligand specificity with thus a possible balancing role in the NK
response. The KIR3D receptor can recognize the HLA-B molecules carrying the Bw4 common epitope (Bw4-I80 and Bw4-T80 variants), but not the
Bw6 motif. The figure shows a greater frequency of patients with CR in patients carrying KIR3Ds with the Bw4-I80 ligand (10%) than in patients with
Bw4-T80 (0%) or Bw6/6 (4%). Among the HLA-Bw4-I80 ligand, the presence of the KIR3DS1 gene is associated with a trend towards improved CR rate
(Chi square test for trend, p 0.016). + and – indicate presence or absence of the gene, respectively.
doi:10.1371/journal.pone.0084940.g002
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absence of their counteracting inhibitor KIR3DL1 receptor gene,
should be more prone to cytolytic activity and CR than other
patients.
State of the art for KIR/HLA genotypes indicate that KIR/
HLA combinations inhibit NK cells with different intensities
[43;44] and that NK-cells will become activated when inhibition is
removed, so activation must involve stimulatory receptors [45].
Furthermore, a decrease trend for NK cytolitic activity was found
against recipient target cells, which have HLA-C2 (strong), HLA-
C1 (modest), HLA-Bw4 (weak cytolitic activity), and then having
no missing-self ligand [46;47]. Therefore, NK cells having
inhibitory KIR receptors with a lower avidity to HLA-ligand
(thus, having a decreased inhibitory function respect to other
KIRs) and having many activator KIR receptors may show an
increased NK-mediated cytolysis of target cells. For example, the
presence of the strong activating receptor KIR2DS1 with its
cognate HLA-C2 ligand were more prone to kill HLA-C2+ cells
[48] and this was associated with increased progression-free
survival (PFS) in chronic lymphocytic leukemia patients [49]. In
addition, the block of inhibitory KIR/HLA interaction has been
showed to decrease leukemic progression in an in vivo animal
model [50]. In patients treated with autologous hematopoietic
stem cell transplantation for high risk for neuroblastoma, the
absence of functional inhibitory KIR/HLA combination was
associated with a lower risk of death and progression [51]. An
increased NK-cell mediated cytotoxic activity obtained by
blocking the inhibitory receptor PD-1 upexpressed on NK-cells
of patients with several solid tumors including CRC [52] was also
Figure 3. Kaplan-Meier survival curves (truncated at 80months) A) Kaplan-Meier plots of OS stratified by radical surgery Yes and
No refer to presence or absence of radical surgery, respectively. B) Kaplan-Meier plots of the association between KIR2DS5 and OS.
OS curves of patients with KIR2DS5 (solid black line), or without the gene (2, red dashed line). The implication of this result could not be further
investigated as the ligand of KIR2DS5 has not been identified yet. C) Kaplan-Meier plots of the association between KIR3DL1/HLA-B and
OS. OS curves of patients with KIR3DL1/HLA-Bw4-I80 (solid black line), KIR3DL1/HLA-Bw4-T80 (dashed red line), or without either one (2/2, green
dashed line). D) Kaplan-Meier plots of the association between a combination of surgery, KIR2DS5 and KIR3DL1/HLA and OS. Yes and
No refer to presence or absence of radical surgery, respectively. 2 refers to the absence of the gene. Kaplan-Meier method, and log-rank were used to
test the differences between subgroups. 0.95 LCL and 0.95 UCL; lower and upper 95th percentile, respectively; CI (95%); 95% confidence interval.
doi:10.1371/journal.pone.0084940.g003
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associated with a durable cancer regression [3]. Our results are
thus consistent with the hypothesis that the presence of activator
KIRs (i.e. high number of aKIRs and the presence of KIR3DS1/
HLA-Bw4-I80, Fig. 1 and 2) has a beneficial effect on tumor
response. It is known that chemotherapy can induce distinct
patterns of HLA cross-presentation of tumor-released antigens to
cytotoxic T-cells [20;53], and that the anti-tumor effects of
chemotherapy could be modified by NK cells [21;22;25]. Down-
regulation of the antigen presentation by the HLA machinery and
a reduction in the number of T-cells infiltrating the tumor site
have been associated with worse prognosis [54;55]. Moreover, NK
cell counts in tumor beds [11;12;53;56] have been shown to be
favorable prognosticators, also in CRC. Our data seem to
complement these observations, suggesting that, depending on a
more responsive NK cell phenotype (number of aKIRs) and
specific activatory/inhibitory KIR/HLA pairs (e.g. KIR3D/HLA-
Bw4), tumor response could be more or less effective, leading to a
different degree of reduction in the size of primary tumors. At the
cellular level, these effects could be mediated by an increased
accumulation of activator KIR receptors on NK cells and effective
HLA-ligands in tumor cells enhancing NK-mediated tumor
immunity. By analogy to the findings, in other situations, the
result of cytolysis may be more effective when a low dose of target
cells is present, but not sufficiently effective in the case with high-
dose of target cells in whom the innate immune response is likely
overwhelmed [57]. By the same way it is plausible that some
peptides (new or only more abundant) may be presented by HLA
to KIR in the course of cancer growth, or even edited due to
mCRC treatment, and thus that peptides/HLA complexes may
influence the NK cell function at site of the tumor [58;59–64].
Among characteristics of patients, only surgery ups OS. Data
from KIR and KIR/HLA genotype by univariate analysis
identified two KIRs associated with survival previously found
associated with CR; the KIR2DS5 and KIR3DL1. After
multivariate comparison with surgery, only the KIR3DL1/HLA-
Bw4-I80 remain statistically significant, indicating that
KIR3DL1/HLA-Bw4-I80 genotype was strongly predictive of
survival independently of surgery (Table 3). Since i) to nowadays
the ligand of KIR2DS5 is unknown, ii). KIR2DS5 is in positive
linkage disequilibrium with the KIR3DL1 gene (LD 30), iii)
KIR3DL1 and 3DS1 are genes of a same locus, iv) KIR3D
genotype and surgery are independent factors (Table 3), we
evaluated their effects by composite KIR genes in OS Kaplan
Meier plots of patients previously treated with combined surgery
and chemotherapy or treated only with chemotherapy because
surgery was not indicated. Results showed patients with a better
OS from the other ones (median OS 79.4 to 22.9 months); the best
increased OS was found when both KIR3DL1 and 3DS1 genes of
the same locus were in the presence of their HLA counterpart
Bw4-I80 (median OS 79.4 months); patients who did receive a
surgical treatment or had a HLA-Bw4-T80 gene (2 independent
factors) had all a worst OS (median OS 14.4 months, Figure 4).
Keeping in mind that CR was found associated with a more
activatory NK cell phenotypes and that CR was associated with an
increased in OS, our working hypothesis is that inhibitory
KIR3DL1/HLA-Bw4-I80 and the absence of KIR2DS5 geno-
types found associated with an increased OS were determinants of
NK cell subset which has a functional potential for an inhibitory
phenotype that is necessary for sustaining disease control and
prolonging survival. This observation is similar to those found
during acute viral infection; indeed, during, for example, acute
human immunodeficiency virus type 1 infection, the NK cell
expansion may be first associated with a non specific expansion of
activating KIR-expressing NK cells, which however is followed by
the occurrence of a protective KIR3DL1+ expressing NK cells,
but only in the presence of their putative, HLA-Bw4-I80 ligand
[65]. Yet, inhibitory KIR HLA pairs were demonstrated to play a
critical role in modulating NK cell function during NK
development, indeed the expression and engagement of inhibitory
receptors by its ligand is necessary for the transition of CD56bright
NK cells to terminally-differentiated and more potent cytotoxic
CD56dimNK cells [16;66] and moreover, inhibitory KIR expres-
sion with a prominent role of KIR3DL1/Bw4, necessitate
recognizing self HLA during their maturation to fully functional
cells with cytotoxic competence and antibody-dependent cell
cytotoxicity (ADCC) [66]. Recently, results of KIR/HLA geno-
typing as outcome predictors of hepatitis C virus-related hepato-
cellular carcinoma support a central role of cytotoxic NK cells
having an inhibitory KIR2DL2/2DL3-HLA-C1+ phenotype in
patients showing a favorable outcome [67] as well as in those with
spontaneously resolving acute HCV infection [68]. We suppose
that in our cases HLA-Bw4-I80 may deliver critical signals to
KIR3DL1+ NK cells allowing them to develop into highly
functional killers that are able to respond aggressively to target
cells, thus resulting in more potent NK cell populations [65;69;70].
Our data of an increased CR in patients with KIR3DS1 and, then
Table 3. Association between KIR/HLA and overall survival (OS).
deaths/total % Median OS Months (95% CI) HR (95%CI) p HR (95%CI) p HR (95%CI) p
Radical surgery
Yes 59.2 25.1 (21.9–29.4) 1{ 1{ 1{
No 82.5 14.4 (11.3–18.9) 2.1 (1.4–3.1) ,0.001 2.0 (1.3–2.9) ,0.001 2.0 (1.3–3.0) ,0.001
KIR2DS5
2 60.3 25.1 (21.7–29.4) 1{ 1{
+ 69.2 17.6 (14.6–22.2) 1.5 (1.0–2.1) 0.03 1.3 (1.0–1.9) 0.10
KIR3DL1/HLA-Bw4
+/I80 52.7 29.4 (22.7–43.0) 1{ 1{
+/T80 73.2 14.7 (11.7–22.3) 2.8 (1.8–4.4) ,0.001 2.7 (1.7–4.2) ,0.001
2/2 65.6 21.6 (18.6–26.7 1.8 (1.2–2.7) 0.007 1.8 (1.2–2.7) 0.006
+ and 2 refer to presence and absence of a gene (respectively).
{Reference category.
doi:10.1371/journal.pone.0084940.t003
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OS, in patients with KIR3DS1 and/or KIR3DS1 plus KIR3DL1
genes that interact with their HLA-Bw4-I80 ligand support this
hypothesis (Figure 4).
Moreover, a body of evidence from genetic association studies
supports the biological significance not only of the interaction of
KIR3DL1 with HLA-Bw4 but also the functional variation seen
with different KIR3DL1 and KIR3DS1 and HLA allotypes
(reviewed in [71]). In this contest activating (KIR3DS1) and
inhibitory (KIR3DL1) receptors may recognize a different set of
HLA molecules (HLA-Bw4-I80, HLA-Bw4-T80) and/or different
HLA-peptide complex binding [36;59]. The dramatic reduction of
HLA-T80 molecule, which is known to have a lower affinity for
KIR3D receptors, on patient outcome in our series, is showed in
the Figures 3C.
Finally, by leading to a reduction in the number of target cells,
in accord with previous findings that KIR receptors and HLA-
ligands may be more effective when the innate immune response is
not likely overwhelmed [57], surgery shows an independent effect
of KIR/HLA genotype to OS of patients. KIR3DL1/BW4-I80
genotype leads to increased OS of the patient when a radical
surgery had been performed, while the presence of a large mass of
tumor cells no treated by surgery flattens the beneficial effect of
KIR/HLA genotype to OS.
This is to our knowledge the first study addressing the relevance
of KIR genotype on the prognosis of mCRC treated with
FOLFIRI regiment. Our results, if confirmed on a larger series of
patients and further studies, suggest a central role of NK cells,
mainly related to KIR3D/HLA-Bw4 genotype, in the immunor-
esponse against mCRC. Advantages of this finding are i) the
identification of predictive markers of tumor response to chemo-
therapy from an easily available sample; ii) the relevance of
combining KIR/HLA genotype and surgery treatment on the
prognosis of mCRC patients rather than surgery alone; iii) the
relevance for novel therapeutic strategies for a modulation of the
anti-tumor immuno-properties when given with chemotherapeutic
Figure 4. Presence of KIR3DS1/HLA-Bw4-I80 genotype associated with CR, improves the survival of patients stratified on
combination of genes and surgical treatment. OS Kaplan-Meier survival curves (truncated at 80months) of patients stratified on patients with
the identified better (A factors) and worse (B factors) prognostic combination of genes and surgical treatment.
doi:10.1371/journal.pone.0084940.g004
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agents; iv) to focus on future research of HLA-Bw4/peptide
complexes interacting with KIR3D receptors.
Moreover, to more precisely define prognosis and better predict
the benefits of adjuvant treatment in mCRC, a quantitative and
qualitative assessment of NK cell based on KIR/HLA genotype
should be related to known CRC-associated genetic markers (i.e.
KRAS mutational status, microsatellite-unstable CRC). Indeed
such genetic markers are able to influence the T-cell response in
addition to driving cancer growth and progression of CRC
[72;73]; thus, the combined characterization of both genetic
features and NK cell genotypes should identify a group of high-risk
patients who would potentially benefit from adjuvant therapy.
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